This document is designed to give guidance to the endTB Project sites on the response to the COVID-19 outbreak. It is intended to be a resource for physicians and other health care professionals. It is a living document that will be regularly updated and enriched. 

This MSF Access Campaign report – now in its seventh edition – covers recent developments, pricing and patent barriers for shorter treatment regimens for TB preventive therapy and newer TB medicines required for the optimal treatment of drug-resistant TB (DR-TB), including an update on pediatric DR-TB formulations.

The endTB Study Group is the group that is responsible for the endTB Observational Study (NCT02754765), which includes more than 2700 patients started on bedaquiline and delamanid containing regimens in 17 countries. Organized by country, this is a list of doctors, nurses, data managers, pharmacists, social workers, administrators and others who have spent many hours collecting and cleaning data, working closely with patients, and ensuring that the endTB Observational Study works smoothly in every aspect of its complex existence.

This MSF Access Campaign report – now in its sixth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs in the framework of the new 2019 WHO DR-TB guidelines.

We provide detailed pricing profiles of key DR-TB drugs available on the Global TB Drug Facility website and estimated prices of DR-TB regimens recommended by WHO in programmatic or operational research frameworks.

This report was produced using among others endTB observational cohort data.